Ixekizumab—抗白细胞介素17单克隆抗体治疗银屑病的新药

摘要

银屑病为多基因遗传背景下的慢性炎症性皮肤病.银屑病的病因尚未完全阐明,目前认为银屑病是遗传因素与环境因素等多种因素相互作用的多基因遗传病.临床上治疗银屑病的传统药物包括阿维A、甲氨蝶呤、环孢素等,但其不良反应较多,临床应用受到限制.研究表明白细胞介素(IL)-17是银屑病发病机制中的关键环节.Ixekizumab(IXE),一种新型抗IL-17单克隆抗体,对中重度斑块状银屑病具有较好的临床疗效和安全性.%Psoriasis is a common, chronic inflammatory skin disease, manifested as red plaques with adherent silvery scales. The exact pathogenesis of psoriasis remains unclear, and interleukin-17(IL-17) is currently considered to play a critical role in it. Newly developed biological agents targeting the IL-17 pathway -Ixekizumab(IXE) has been used to treat psoriasis in clinical trials, which has been proved to be effective and safe in the treatment of psoriasis vulgaris and psoriatic arthritis. However, there is still a need for a long-term evaluation of IXE's safety.